

Hull and East Riding Prescribing Committee Minutes – Confirmed

Date / Time Wednesday 21st July 2021, 1pm
Venue WEBEX
Chair Dr S Raise, GP Prescribing Lead, ER
Notes / Action Points Mrs W Hornsby, Senior Pharmacy Technician, HUTH
Quorate: Yes / No Yes

Miss J Morgan, Senior Principal Pharmacist, HUTH
Dr B Ali, GP Prescribing Lead, ER CCG
Mr P McGorry, Pharmacist, LPC
Mr K McCorry, Senior Pharmacist, NECS
Dr W Chong, Chief Pharmacist, HFTH
Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics, HUTH
Prof M Lind, Professor of Oncology, HUTH
Guest Mr M Heppel, Senior Pharmacist Endocrinology, HUTH

Apologies Mr P Davis, Strategic Lead Primary Care, Hull, CCG
Dr R Shreiber, Professional Secretary LMC
Mrs E Baggaley, Head of Medicines Service, CHCP
Mrs C Hayward, Pharmacist, LPC

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
2021.07.01	Apologies	As above				March 21
2021.07.02	Declarations of Interest	None				March 21
2021.07.03	Minutes of the Previous Meeting	Accepted as a true record				March 21
2021.07.04	Matters Arising & Action Tracker	<p>Correspondence Received Rheumatology are preparing pathway with rituximab and MTX, however NICE have just published new guidance relating to moderate disease so this will also need to be incorporated in the pathway</p> <p>Humber CCG Evidence Based Interventions KMc has discussed wording of document with commissioners</p> <p>Action Tracker RS to discuss SCF with GCP – RS not present leave on to discuss next time</p> <p>PG/SCF WH has added Ketorolac and Glycopyrronium Guidelines to website</p> <p>NatPSA Emergency Steroid Card JM has prepared guideline and it is on agenda for discussion</p> <p>Traffic Light Status WH has updated the red list with pemigatanib and erenumab</p> <p>Feedback from commissioning groups KMc and JM to work with CCG to approve MS guideline</p> <p>PG/SCF JM has worked with cardiology to update HF guideline and it will be on</p>	<p>Ongoing</p> <p>Action complete</p> <p>Ongoing</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Ongoing</p> <p>Action complete</p>	<p>Update next time</p> <p>Update next time</p> <p>No further action</p> <p>No further action</p> <p>No further action</p> <p>Update next time</p> <p>No further</p>	<p>JM</p> <p>KMc</p> <p>RS</p> <p>WH</p> <p>JM</p> <p>WH</p> <p>KMc/JM</p> <p>JM</p>	<p>Nov 21</p> <p>July 21</p> <p>Jan 21</p> <p>July 21</p> <p>July 21</p> <p>July 21</p> <p>July 21</p> <p>July 21</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
		<p>the September agenda for discussion</p> <p>PG/SCF KMc has invited JM to pathways group to discuss ONS pathways, the meeting has yet to take place</p> <p>PG/SCF JM has added link to ditch the dipstick guideline and it has been added to website</p> <p>PG/SCF WH has added approved guidelines to the website</p> <p>PG/SCF JM is still chasing to discuss with Mr Smith and Mr Simms the degarelix SCF</p> <p>PG/SCF WH has extended review dates on all DMARD SCF until Jan 22</p> <p>Correspondence Received JM had feedback comments on denosumab SCF to Dr Aye and Sr Saharia and Dr Aye is reviewing them</p> <p>AOB JM has discussed adding ceftriaxone to guideline as option cefotaxime with ACAT</p> <p>AOB WH has altered status of ceftriaxone and cefotaxime on joint formulary to blue</p> <p>AOB JM has sent HUTH anticoagulation checklist to SR and will check MMIG minutes for discussion that took place</p>	<p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Ongoing</p> <p>Action complete</p> <p>Feedback next time</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p>	<p>action</p> <p>No further action</p> <p>No further action</p> <p>No further action</p> <p>Discuss next time</p> <p>No further action</p> <p></p> <p>No further action</p> <p>No further action</p> <p>No further action</p>	<p>KMc</p> <p>JM</p> <p>WH</p> <p>JM</p> <p>WH</p> <p>JM</p> <p>JM</p> <p>WH</p> <p>JM</p>	<p>July 21</p> <p>July 21</p> <p>July 21</p> <p>July 21</p> <p>July 21</p> <p>July 21</p> <p>July 21</p> <p>July 21</p> <p>July 21</p>
2021.07.05	Traffic Light Status	<p>Ketofall® Ketotifen Single Use Eye Drops — Mr C Vize JM will discuss with Mr Vize the need for a guideline</p> <p>Nustendi® Bempedoic Acid & Ezetimibe Nilemdo ® Bempedoic Acid Both will have to be red to enable HUTH to access the PAS scheme</p>	<p>Approved as blue</p> <p>Approved as red</p>	<p>WH to update joint formulary and red list</p>	<p>WH</p>	<p>Sept 21</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
		<p>Kesimpta® Ofatumumab for MS</p> <p>Naldemedine Opioid induced constipation</p> <p>Cefazolin- MSSA/S.lugdunensis Endocarditis in patient with a mild/moderate penicillin allergy</p> <p>Natalizumab Subcutaneous MS</p> <p>Tafamadis Transthyretin amyloidosis with cardiomyopathy Remove from main body of formulary available via chairs approval only due to NICE not recommending</p> <p>Cyanocobalamin 1000microgram oral preparation deficiency B12 and folate guideline to be updated</p>	<p>Approved as red</p> <p>Approved as blue</p> <p>Approved as red</p> <p>Approved as red</p> <p>WH to amend joint formulary</p> <p>Approved as green</p>			
2021.07.06	Feedback From Commissioning Groups	<p>New product requests from April D&T were approved by both Hull and ER</p> <p>Ditch the dipstick was approved</p> <p>APC proposal document was approved</p> <p>Migraine and Cluster headache guideline approved</p> <p>Fremanezumab went to both and the both CCG would like to know why not many patients have been stopped in relation to expectations, contracting are going to look at the figures and investigate.</p>	Noted	No further action		July 21
2021.07.07	Prescribing guidelines, shared care frameworks for approval	<p>NEW</p> <p>Moderate-severe allergic rhinitis uncontrolled by maximal conventional therapy pathway (Acarizax)</p> <p>New guideline to demonstrate place of acarizax in treatment pathway the committee asked if the medicines in the pathway could be colour coded as some were red and some were amber to avoid confusion</p> <p>Emergency Steroid Card Guideline</p> <p>Written in line with trust guideline only difference contact numbers.</p> <p>UPDATES</p> <p>Type 2 Diabetes Guideline</p> <p>MH from HUTH the author of the guideline attended the meeting as a guest to discuss the updated guideline and answer any questions. MH explained that due to the surge in new diabetic medicines the approach to treatment had now shifted. The guideline has been updated in line with new evidence unfortunately MH explained that the NICE guidance</p>	<p>Approved</p> <p>Approved</p> <p>JM/MH to add references</p>	<p>JM to ask Dr Khan to audit Acarizax use and feedback</p> <p>WH to update website</p>	<p>JM</p> <p>WH</p> <p>JM/MH</p>	<p>Sept 21</p> <p>Sept 21</p> <p>Sept 21</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
		<p>has not yet been updated in line with changes and it would be next year before this happened. MH also explained that empagliflozin was due and update to its licence to include HF and he had done an update to the guideline for when this went live. The only negative feedback received from primary care was there may be issues if printed in black and white. Due to the difference between the updated guideline and NICE the committee ask if references could be added to the document to back up the recommendations and an explanation of why the approach differs from previous recommendations. SR said he felt this was a fantastic piece of work</p> <p>COPD Guideline JM to check pulmonary rehab phone number is correct, Bevespi is a new addition as is Trixeo triple therapy inhaler. The committee ask if the reference to not using prednisolone and antibiotics as JIC therapy could be in a more prominent position. The committee also ask why Duaklir was removed and JM will discuss this with AM and feedback.</p> <p>Adult Asthma Guideline Fobumix has been added, Relvar has been removed although it is still in use by paediatrics so will remain on formulary</p> <p>Lithium Shared Care Framework This has been reviewed and checked by both HUTH and HFTH. WC mentioned that HFTH would like to introduce an electronic care plan via Lorenzo as they are going to start a lithium register for all patients being treated via HFTH. Contact details for Mental Health Response Team to be added</p> <p>Diagnosis of airway disease guideline No changes have been made</p> <p>Renal analgesic ladder KMc asked for better clarification on the recommendation to avoid codeine and dihydrocodeine JM will update the word chronic to be removed from title</p> <p>Guidelines for the Prescribing, Supply and Administration of Methadone and Buprenorphine on Transfer of Care Has been reviewed by RENEW and ER partnership, extra section on lack of communication resulting in delay to treatment added and all fax numbers have been removed.</p>	<p>JM to check number, amend JIC recommendation and discuss Duaklir with AM</p> <p>Approved</p> <p>JM to add contact details. Approved</p> <p>Approved</p> <p>JM to amend Approved with amendments</p> <p>Approved</p>		<p>JM</p> <p>JM</p> <p>JM</p>	<p>Sept 21</p> <p>Sept 21</p> <p>Sept 21</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
		<p>Ibandronate for post menopausal women with breast cancer Shared care framework MHRA warning have been added and information around counselling updated</p> <p>Ibandronate for metastatic bone disease shared care framework JM to update monitoring section</p>	<p>Approved</p> <p>Approved with amendments</p>		JM	Sept 21
2021.07.08	MHRA DSU	<p>May 21 Levothyroxine new prescribing advice for patients who experience symptoms on switching between different levothyroxine products.</p> <p>June 21 CDK 4/6 inhibitors reports of interstitial lung disease and pneumonitis including severe cases</p> <p>Atezolizumab and other immune stimulatory anti cancer drugs – risk of severe cutaneous adverse reactions</p>	Noted			July 21
2021.07.09	NPSA	<p>Inappropriate Anticoagulation of Patients with Mechanical Heart Valve Sent to CHCP for Hull and some ER patients</p>	Noted			July 21
2021.07.10	Hydroxy chloroquine SCF	<p>Concerns have been raised around compliance to the SCF and there are concerns the monitoring is not being performed especially around the ophthalmology checks. JM will discuss with rheumatology. KMc also asked what the plan was going forward. JM said hydroxychloroquine is on the RMOC plan going forward so there should be a draft document released shortly.</p> <p>JM said it would be helpful if a primary care list of patients could be generated to help see how big the problem is.</p>	<p>JM to discuss with rheumatology</p> <p>KMc to check prescribing figures in community</p>		JM KMc	Sept 21 Sept 21
2021.07.11	Dementia SCF	<p>EB could not attend meeting to discuss so add to agenda for September. WC ask what the problems were and JM said it referred to the memory clinic not following SCF</p>	JM to email Wendy Storey		JM	Sept 21
2021.07.12	Regional Medicines Optimisation Committee	<ul style="list-style-type: none"> • RMOC shared care guidance: draft shared care protocols, consultation 2 • RMOC shared care guidance: draft shared care protocols, consultation 3 				
2021.07.13	Antibiotic Prescription requests from HUTH Maternity Services	<p>BA said there is a huge OP community maternity service that currently will provide urine sample swabs but then request GP to prescribe antibiotics due to failures in communications it can sometime be weeks before the GP receives the request, BA wondered if there was anyway this service could be improved and also felt that the health professional carrying out the swabs had the responsibility of making sure the patient</p>	JM to discuss with maternity services		JM	Sept 21

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
		received effective treatment in a timely manner. JM will discuss with Mrs Allen and HUTH W&C pharmacist to help devise solution				
2021.07.14	Correspondence Received	None	Noted			July 21
2021.07.15	Primary Care Rebate Scheme	KMc the rebate schemes for both Apidra and Insuman have been renewed.	Noted			July 21
2021.07.16	Additional Minutes for Information	<ul style="list-style-type: none"> a) MMIG b) HEY D&T c) HTFT DTC d) CHCP e) Formulary Sub Group f) Hull CC Planning & Commissioning 	Noted			July 21
2021.07.17	A.O.B	SR mentioned Spire consultants were writing to GPs recommending they prescribe treatments but as we no longer have a representative from the Spire this could not be discussed.	Noted			July 21
	Date and Time of Next Meeting	Wednesday 22 nd September 2021, 1pm, WEBEX				

st